Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...
In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

3SBio Gains China Rights to Another Drug for Dialysis Patients

publication date: Feb 8, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
3SBio Inc. (沈阳三生制药) in-licensed the China rights to a phosphate binder, Nephoxil®, from Panacor Bioscience Ltd. of Taiwan. Phosphate binders are routinely prescribed for end stage renal disease, the same population served by 3SBio’s major products, the recombinant anemia drugs EPIAO and TPIAO. More details...

Stock Symbol: (NSDQ: SSRX)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners